NCT06232551 · Scott C. Woller, MD
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
(eVTE)
What this study is about
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal.
View original scientific description
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal. The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low. The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Discharging clinician must be in one of the following iCentra electronic health record (Cerner, Kansas City, MO) positions:
- Physician, nurse practitioner, or physician assistant hospitalist
- Physician internal medicine
- Physician family medicine
- Patient age ≥ 18 years.
- The encounter must be inpatient.
- A signed hospital discharge order must be present.
- eVTE target population criteria (increased venous thromboembolism risk, low bleeding risk) must be met
Exclusion criteria
- Pregnant during encounter
- Discharge order completed by ineligible clinician type
- Exclude all cases where the patient is being actively prescribed and intended to be discharged on the following qualifying anticoagulant medications, regardless of dose form or dosing regimen (i.e., they have an active prescription for one of these medications):
- Fondaparinux
- Rivaroxaban
- Creatinine clearance \<30 milliliters/minute based on last-available eligible serum creatinine value preceding discharge
- Estimated creatine clearance based on actual body weight (preferred) ((140 - age years) \
- measured weight kilograms) / (72.0 \
- serum creatine milligrams/deciliter) (\*0.85 if female)) = milliliters/minute
- If measured body weight not available, then based on ideal body weight ((140 - age years) \
- ideal body weight kilograms) / (72.0 \
- serum creatine milligrams/deciliter) (\*0.85 if female)) = milliliters/minute
Where
- Murray, Utah
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 17, 2024 · Source of record for eligibility and locations